6533b839fe1ef96bd12a6d1b
RESEARCH PRODUCT
Bisphosphonates in the era of antiangiogenic targeted therapy
Frederik C. Roossubject
Oncologymedicine.medical_specialtybusiness.industryUrologymedicine.medical_treatmentmedicine.diseaseTargeted therapyRenal cell carcinomaInternal medicinemedicineIn patientmedicine.symptomBone painbusinessKidney cancerdescription
Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma. Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-06-01 | Nature Reviews Urology |